Evidence map›Paper›PMID 38243979›Full record

ReviewCurrent medicinal chemistry2025

Natural and Synthetic Coumarins as Potential Drug Candidates against SARS-CoV-2/COVID-19.

Iara da Silva Santos, Leticia Oliveira Magalhaes, Roberta Katlen Fusco Marra, Camilo Henrique da Silva Lima, Lidilhone Hamerski, Magaly Girao Albuquerque, Barbara Vasconcellos da Silva

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Iara da Silva SantosDepartment of Organic Chemistry, Instituto de Pesquisas de Produtos Naturais Walter Mors, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Leticia Oliveira MagalhaesDepartment of Organic Chemistry, Universidade Federal do Rio de Janeiro, Instituto de Química, Rio de Janeiro, Brazil.
Roberta Katlen Fusco MarraDepartment of Organic Chemistry, Universidade Federal do Rio de Janeiro, Instituto de Química, Rio de Janeiro, Brazil.ORCID 0000-0002-1430-2566
Camilo Henrique da Silva LimaDepartment of Organic Chemistry, Universidade Federal do Rio de Janeiro, Instituto de Química, Rio de Janeiro, Brazil.ORCID 0000-0002-5579-7809
Lidilhone HamerskiDepartment of Organic Chemistry, Instituto de Pesquisas de Produtos Naturais Walter Mors, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.ORCID 0000-0001-5807-6161
Magaly Girao AlbuquerqueDepartment of Organic Chemistry, Universidade Federal do Rio de Janeiro, Instituto de Química, Rio de Janeiro, Brazil.ORCID 0000-0003-1558-0928
Barbara Vasconcellos da SilvaDepartment of Organic Chemistry, Universidade Federal do Rio de Janeiro, Instituto de Química, Rio de Janeiro, Brazil.ORCID 0000-0002-3020-9310
Universidade Federal do Rio de Janeiro · BR

Funding

CAPES, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior 001FAPERJ, Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro SEI-260003/007043/2022, SEI-260003/003788/2022, E-26/010.002270/2019
6 · The paper itself

Abstract

COVID-19, an airborne disease caused by a betacoronavirus named SARS-- CoV-2, was officially declared a pandemic in early 2020, resulting in more than 770 million confirmed cases and over 6.9 million deaths by September 2023. Although the introduction of vaccines in late 2020 helped reduce the number of deaths, the global effort to fight COVID-19 is far from over. While significant progress has been made in a short period, the fight against SARS-CoV-2/COVID-19 and other potential pandemic threats continues. Like AIDS and hepatitis C epidemics, controlling the spread of COVID-19 will require the development of multiple drugs to weaken the virus's resistance to different drug treatments. Therefore, it is essential to continue developing new drug candidates derived from natural or synthetic small molecules. Coumarins are a promising drug design and development scaffold due to their synthetic versatility and unique physicochemical properties. Numerous examples reported in scientific literature, mainly by

Indexed as

Antiviral AgentsBiological ProductsCoumarinsCOVID-19 Drug TreatmentCOVID-19HumansPandemicsSARS-CoV-2Antiviral AgentsBiological ProductsCoumarinsantiviral drugscomputer simulationsCoronavirus disease 2019coumarinscysteine-proteases.molecular dockingmolecular dynamicssevere acute respiratory syndrome coronavirus 2

Identifiers

PMID38243979
OpenAlexW4391067391

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.